Does Rallies show 13F holders for ARQT?

Yes. Rallies tracks hedge fund and 13F ownership data for ARQT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ARQT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARQT. It does not provide personalized investment advice.

ARQT (Arcutis Biotherapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is a publicly traded Healthcare sector company. As of May 21, 2026, ARQT trades at $20.80 with a market cap of $2.51B and a P/E ratio of -676.83. ARQT moved +5.00% today. Year to date, ARQT is -32.22%; over the trailing twelve months it is +41.08%. Its 52-week range spans $8.03 to $31.77. Analyst consensus is strong buy with an average price target of $34.63. Rallies surfaces ARQT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ARQT stock?

Hedge funds tracked by Rallies that own ARQT include Mangrove Partners and Farallon Capital. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arcutis Biotherapeutics, Inc. Common Stock.

ARQT Key Metrics

Key financial metrics for ARQT
Metric	Value
Price	$20.80
Market Cap	$2.51B
P/E Ratio	-676.83
EPS	$-0.03
Dividend Yield	0.00%
52-Week High	$31.77
52-Week Low	$8.03
Volume	821
Avg Volume	0
Revenue (TTM)	$415.62M
Net Income	$-2.38M
Gross Margin	90.94%

Top Hedge Funds Holding ARQT

Mangrove Partners holds 59.07K shares of ARQT, changed +0.00% as of Dec 31, 2024.
Farallon Capital holds 26.00K shares of ARQT, changed +0.00% as of Mar 31, 2026.

Latest ARQT News

Arcutis ZORYVE Sales Reach $105.4M in Q1 with Infant sNDA Submission — May 6, 2026
Arcutis ZORYVE cream clears 49% of infants’ eczema by Week 4 — Mar 28, 2026
Arcutis to Unveil Late-Breaking Phase 2 Infant ZORYVE 0.05% Data at AAD — Mar 18, 2026
ZORYVE Cream 56-Week Study Shows 63% Clearance in 2–5 Year-Olds — Mar 10, 2026
Arcutis Elevates Mas Matsuda to EVP and Chief Legal Officer Overseeing ZORYVE Growth — Mar 5, 2026

Recent ARQT Insider Trades

Vairavan Latha sold 435 (~$9.16K) on May 11, 2026.
Burnett Patrick sold 222 (~$4.67K) on May 11, 2026.
Matsuda Masaru sold 7.37K (~$171.54K) on May 4, 2026.

ARQT Analyst Consensus

8 analysts cover ARQT: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.63.

Common questions about ARQT

Who owns ARQT stock?: Hedge funds tracked by Rallies that own ARQT include Mangrove Partners and Farallon Capital. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arcutis Biotherapeutics, Inc. Common Stock.
Does Rallies show 13F holders for ARQT?: Yes. Rallies tracks hedge fund and 13F ownership data for ARQT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ARQT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARQT. It does not provide personalized investment advice.